Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04980521 · ClinicalTrials.gov registry record · NA
Promoting Radon Testing Via Smartphone App: A Clinical Trial in a High Radon State
A NA study of Lung Cancer, sponsored by University of North Dakota.
- Completed
- Registry status
- NA
- Development phase
- 138
- Enrollment target
- 1
- Study location
NCT04980521: Completed NA study of Lung Cancer, sponsored by University of North Dakota.
NCT04980521 is a NA study of Lung Cancer that has completed, run by University of North Dakota. The registered enrollment target is 138 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04980521, a NA study of Lung Cancer, has completed, sponsored by University of North Dakota.
- COMPLETED
- Registry status
- NA
- Development phase
- 138 participants
- Enrollment target
- 1
- Study location
Study Summary
This research will compare (1) the effectiveness of a mobile radon-education app (vs. traditional brochures) and (2) that of the radon app with in-app reminders (vs. the radon app without in-app reminders and the no app use with postal reminders) to increase radon awareness and testing among North Dakotans. The prevalence of exceptionally high levels of residential radon in North Dakota (ND), coupled with public's poor understanding of this hazard, is a critical public health problem.
Primary Outcome
The rate at which participants order a free radon test kit
Conditions Studied
Interventions
- OTHER The radon app
- OTHER Print brochure
Study Locations (1)
North Dakota
- University of North Dakota - Grand Forks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2023-03-31 |
| Phase | NA |
What the finished NCT04980521 record still lists
NCT04980521 is an interventional study that assigns participants to a tested intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which The radon app is the first listed.
NCT04980521 reports a single indexed study location in North Dakota.
Frequently Asked Questions
What is clinical trial NCT04980521 about?
NCT04980521 is a clinical study titled "Promoting Radon Testing Via Smartphone App: A Clinical Trial in a High Radon State". This research will compare (1) the effectiveness of a mobile radon-education app (vs. traditional brochures) and (2) that of the radon app with in-app reminders (vs. the radon app without in-app reminders and the no app use with postal reminders) to increase radon awareness and testing among North D...
What is the current status of trial NCT04980521?
This trial is currently completed. It is a NA study. The enrollment target is 138 participants. The study started on 2021-10-01. Estimated completion is 2023-03-31.
What conditions does trial NCT04980521 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT04980521?
The interventions under investigation include: The radon app (OTHER), Print brochure (OTHER).
Who is sponsoring clinical trial NCT04980521?
This trial is sponsored by University of North Dakota, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04980521 being conducted?
This trial has 1 study location across North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04980521's enrollment target sits among peer trials
138 156th of 409 higher than 254 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
-
Lung Cancer Screening in High-risk Black Individuals
RECRUITING · NA
-
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
RECRUITING · NA
-
Exercise as Maintenance Therapy in Advanced Lung Cancer
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Stereotactic Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04402788 · 138 participants · Phase 2
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
- NCT04883255 · 138 participants · Early Phase 1
Cannabis Use, Cognition, and the Endocannabinoid System in HIV
- NCT05620784 · 138 participants · Phase 3
Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
- NCT05832086 · 138 participants · Phase 2
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI